{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003717","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.637250+00:00","generated_at":"2026-05-28T04:47:33.818960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biodesix reports FY2024 revenue $71.3M (+45% YoY), exceeds guidance midpoint","bullets":["Total revenue $71.3M in FY2024, up 45% YoY; Q4 revenue $20.4M, up 39% YoY.","Lung Diagnostic revenue $64.7M (+43% YoY); test volumes 54,300 (+40% YoY).","Biopharma Services revenue $6.6M (+69% YoY); $12.2M contracted backlog for 2025 (+54%).","Cash and equivalents $26.2M as of Dec 31, 2024.","Results are preliminary and unaudited; Q4 and FY2024 figures subject to final audit."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003717","json":"https://secwatch.observer/filing/0000950170-25-003717.json","markdown":"https://secwatch.observer/filing/0000950170-25-003717.md","text":"https://secwatch.observer/filing/0000950170-25-003717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017025003717/0000950170-25-003717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017025003717/bdsx-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:47:33.818960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}